Skip to content
naulon
Not checkedNot checked for notices yet.

Efficacy Of Freeze-Dried Inactivated Rift Valley Fever Vaccine

Atwa, M.H, Maha Raafat Abd El-Fadeel, Heba A. Khafagy and 3 more

Journal of Applied Veterinary Sciences · 2020

doi:10.21608/javs.2020.85571 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Rift Valley Fever (RVF) is an acute infectious zoonotic arthropod-born viral disease, affecting many species of animals and it causes great economic losses in animal wealth and has a zoonotic implication. Eradication of mosquito and vaccination is an important and best method for preventing and controlling the disease. This study was applied for the preparation and evaluation of Rift Valley Fever inactivated vaccine in a lyophilized form that is reconstituted at the time of inoculation using saponin that acts as an adjuvant. The prepared vaccine was proved to be sterile and safe. ED50 Potency test of the prepared vaccine in mice gave 0.0010 ED50/ML (permissible limit less than 0.02/ml). Sheep were vaccinated with 1ml S\C of the prepared lyophilized inactivated RVF vaccine and another group was vaccinated S|C with 1ml of Aluminum hydroxide inactivated RVF vaccine. The immune response of different vaccinated sheep groups was evaluated using SNT and ELISA. The Prepared lyophilized inactivated RVF vaccine gave protective NI at the second-week post-vaccination (2.1 and 0.286 OD), then reach to peak at the 4th week (3.28 and 0.343OD) then began to decline till ten months (1.8 and 0.241 OD), while the Aluminum hydroxide inactivated RVF vaccine gave protective NI at the second-week post-vaccination (1.7 and 0.277 OD) then reach to its NI peak at the 4th week (3.13 and 0.312 OD) then began to decline till ten months (1.73 and 0.228 OD). From the obtained results, it was found that the prepared lyophilized inactivated RVF vaccine was safe, potent and gave approximately similar immune response as aluminum hydroxide inactivated RVF vaccine but it is better as it reduces time and effort consuming during vaccine production.

Abstract licence: CC BY

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.